Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Puhr

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Prostate Cancer and Prostatic Diseases|August 26, 2023
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancerAnita Csizmarik, Nikolett Nagy, Dávid Keresztes, et al.
Oncogene|November 28, 2023
Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblastsAndrea Eigentler, Florian Handle, Silvia Schanung, et al.
Frontiers in Oncology|February 24, 2022
Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer CellsOlesya Vakhrusheva, Holger H H Erb, Vitus Bräunig, et al.
Cells|December 23, 2022
Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian CancerElisa Pardella, Erica Pranzini, Ilaria Nesi, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 20, 2024
Pre-existing cell subpopulations in primary prostate cancer tumors display surface fingerprints of docetaxel-resistant cellsStanislav Drápela, Barbora Kvokačková, Eva Slabáková, et al.
European Urology Oncology|June 9, 2024
Prediction of Clinically Significant Prostate Cancer by a Specific Collagen-related Transcriptome, Proteome, and Urinome SignatureIsabel Heidegger, Maria Frantzi, Stefan Salcher, et al.
Endocrine-Related Cancer|October 21, 2015
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancerJan Kroon, Martin Puhr, Jeroen T Buijs, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 16, 2024
Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor SymposiumJustus Simon Israel, Laura-Maria Marcelin, Christian Thomas, et al.
Journal of Cellular and Molecular Medicine|December 31, 2021
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancerDávid Keresztes, Anita Csizmarik, Nikolett Nagy, et al.
EMBO Molecular Medicine|April 16, 2015
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostatSimone Meidhof, Simone Brabletz, Waltraut Lehmann, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Prostate Cancer and Prostatic Diseases|August 26, 2023
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancerAnita Csizmarik, Nikolett Nagy, Dávid Keresztes, et al.
Oncogene|November 28, 2023
Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblastsAndrea Eigentler, Florian Handle, Silvia Schanung, et al.
Frontiers in Oncology|February 24, 2022
Artesunate Inhibits the Growth Behavior of Docetaxel-Resistant Prostate Cancer CellsOlesya Vakhrusheva, Holger H H Erb, Vitus Bräunig, et al.
Cells|December 23, 2022
Therapy-Induced Stromal Senescence Promoting Aggressiveness of Prostate and Ovarian CancerElisa Pardella, Erica Pranzini, Ilaria Nesi, et al.
Cellular Oncology (Dordrecht, Netherlands)|August 20, 2024
Pre-existing cell subpopulations in primary prostate cancer tumors display surface fingerprints of docetaxel-resistant cellsStanislav Drápela, Barbora Kvokačková, Eva Slabáková, et al.
European Urology Oncology|June 9, 2024
Prediction of Clinically Significant Prostate Cancer by a Specific Collagen-related Transcriptome, Proteome, and Urinome SignatureIsabel Heidegger, Maria Frantzi, Stefan Salcher, et al.
Endocrine-Related Cancer|October 21, 2015
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancerJan Kroon, Martin Puhr, Jeroen T Buijs, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 16, 2024
Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor SymposiumJustus Simon Israel, Laura-Maria Marcelin, Christian Thomas, et al.
Journal of Cellular and Molecular Medicine|December 31, 2021
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancerDávid Keresztes, Anita Csizmarik, Nikolett Nagy, et al.
EMBO Molecular Medicine|April 16, 2015
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostatSimone Meidhof, Simone Brabletz, Waltraut Lehmann, et al.
Pageof 7